Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report. Update on Selected Topics 2002. National Heart, Lung and Blood Institute. Disponible en http://www.nhlbi.nih.gov/guidelines/asthma/index.htm
[2.]
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. 2002. Disponible en http://www.ginasthma.com
[3.]
Zafirlukast product monograph,
[4.]
J.C. Adkins, R.N. Brogden.
Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.
Drugs, 55 (1998), pp. 121-144
[5.]
D.F. Schoors, M. De Smet, T. Reiss, D. Margolskee, H. Cheng, P. Larson, et al.
Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers.
Br J Clin Pharmacol, 40 (1995), pp. 277-280
[6.]
J.J. Zhao, J.D. Rogers, S.D. Holland, P. Larson, R.D. Amin, R. Haesen, et al.
Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.
Biopharm Drug Dispos, 18 (1997), pp. 769-777
[7.]
H. Cheng, J.A. Leff, R. Amin, B.J. Gertz, M. De Smet, N. Noonan, et al.
Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
Pharm Res, 13 (1996), pp. 445-448
[8.]
K.P. Hui, N.C. Barnes.
Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist.
Lancet, 337 (1991), pp. 1062-1063
[9.]
J.P. Kemp, P.E. Korenblat, J.E. Scherger, M. Minkwitz.
Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma.
J Fam Pract, 48 (1999), pp. 425-432
[10.]
L. García-Marcos, A. Schuster.
Antileukotrienes in asthma: present situation.
Expert Opin Pharmacother, 2 (2001), pp. 441-466
[11.]
J.M. Edelman, J.A. Turpin, E.A. Bronsky, J. Grossman, J.P. Kemp, A.F. Ghannam, et al.
Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group.
Ann Intern Med, 132 (2000), pp. 97-104
[12.]
H. Bisgaard, K.G. Nielsen.
Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children.
Am J Respir Crit Care Med, 162 (2000), pp. 187-190
[13.]
J.r. Henderson WR, L.O. Tang, S.J. Chu, S.M. Tsao, G.K. Chiang, F. Jones, et al.
A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model.
Am J Respir Crit Care Med, 165 (2002), pp. 108-116
[14.]
B. Knorr, L.M. Franchi, H. Bisgaard, J.H. Vermeulen, P. LeSouef, N. Santanello, et al.
Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
Pediatrics, 108 (2001), pp. E48
[15.]
H. Bisgaard, L. Loland, J.A. Oj.
NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast.
Am J Respir Crit Care Med, 160 (1999), pp. 1227-1231
[16.]
D.S. Pearlman, K.L. Lampl, P.J. Dowling, C.J. Miller, C.M. Bonuccelli.
Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.
Clin Ther, 22 (2000), pp. 732-747
[17.]
B. Knorr, J. Matz, J.A. Bernstein, H. Nguyen, B.C. Seidenberg, T.F. Reiss, et al.
Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.
Jama, 279 (1998), pp. 1181-1186
[18.]
F.M. Ducharme, G.C. Hicks.
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
Cochrane Database Syst Rev, (2002), pp. cD002314
[19.]
F.E. Simons, J.R. Villa, B.W. Lee, A.M. Teper, B. Lyttle, G. Aristizabal, et al.
Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.
J Pediatr, 138 (2001), pp. 694-698
[20.]
F. Ducharme.
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.
Cochrane Database Syst Rev, (2001), pp. cD003133
[21.]
H.S. Nelson, W.W. Busse, E. Kerwin, N. Church, A. Emmett, K. Rickard, et al.
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
J Allergy Clin Immunol, 106 (2000), pp. 1088-1095
[22.]
J.E. Fish, E. Israel, J.J. Murray, A. Emmett, R. Boone, S.W. Yancey, et al.
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
Chest, 120 (2001), pp. 423-430
[23.]
D.A. Stempel, J.C. O'Donnell, J.W. Meyer.
Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.
J Allergy Clin Immunol, 109 (2002), pp. 433-439
[24.]
S. O'Sullivan, M. Akveld, C.M. Burke, L.W. Poulter.
Effect of the Addition of Montelukast to inhaled Fluticasone Propionate on airway inflammation.
Am J Respir Crit Care Med, 167 (2003), pp. 745-750
[25.]
J. Churg, L. Strauss.
Allergy granulomatosis, allergic angiitis and polyarteritis nodosa.
Am J Pathol, 27 (1951), pp. 277-301
[26.]
H. Bisgaard.
A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis.
Am J Respir Crit Care Med, 167 (2003), pp. 379-383
[27.]
S. Szefler, E.A. Simoes.
Montelukast for respiratory syncytial virus bronchiolitis. Significant effect or provocative findings?.
Am J Respir Crit Care Med, 167 (2003), pp. 290-291
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados